These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34348632)

  • 41. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.
    Wu KC; Gerstenblith G; Guallar E; Marine JE; Dalal D; Cheng A; Marbán E; Lima JA; Tomaselli GF; Weiss RG
    Circ Cardiovasc Imaging; 2012 Mar; 5(2):178-86. PubMed ID: 22267750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: Improve SCA clinical trial.
    Zhang S; Ching CK; Huang D; Liu YB; Rodriguez-Guerrero DA; Hussin A; Kim YH; Chasnoits AR; Cerkvenik J; Lexcen DR; Muckala K; Brown ML; Cheng A; Singh B;
    Heart Rhythm; 2020 Mar; 17(3):468-475. PubMed ID: 31561030
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Strain echocardiography improves risk prediction of ventricular arrhythmias after myocardial infarction.
    Haugaa KH; Grenne BL; Eek CH; Ersbøll M; Valeur N; Svendsen JH; Florian A; Sjøli B; Brunvand H; Køber L; Voigt JU; Desmet W; Smiseth OA; Edvardsen T
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):841-50. PubMed ID: 23850251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future.
    Halliday BP; Cleland JGF; Goldberger JJ; Prasad SK
    Circulation; 2017 Jul; 136(2):215-231. PubMed ID: 28696268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction.
    Jilek C; Lewalter T; Pauschinger M; von Scheidt W; Frankenstein L; Pfister O; Hambrecht R; Bruder O; Brachmann J; Hartmann A; Strasser R; Hochadel M; Senges J
    Clin Res Cardiol; 2020 Jan; 109(1):115-123. PubMed ID: 31236690
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The new ESC guidelines on the management of ventricular tachyarrhythmias : Implications for daily practice].
    Könemann H; Frommeyer G; Zeppenfeld K; Eckardt L
    Herz; 2023 Feb; 48(1):3-14. PubMed ID: 36441174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between cardiac autonomic function and sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillators.
    Battipaglia I; Barone L; Mariani L; Infusino F; Remoli R; Careri G; Pinnacchio G; Tarzia P; Lanza GA; Crea F
    Europace; 2010 Dec; 12(12):1725-31. PubMed ID: 21097480
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimizing patient selection for primary prevention implantable cardioverter-defibrillator implantation: utilizing multimodal machine learning to assess risk of implantable cardioverter-defibrillator non-benefit.
    Kolk MZH; Ruipérez-Campillo S; Deb B; Bekkers EJ; Allaart CP; Rogers AJ; Van Der Lingen ACJ; Alvarez Florez L; Isgum I; De Vos BD; Clopton P; Wilde AAM; Knops RE; Narayan SM; Tjong FVY
    Europace; 2023 Aug; 25(9):. PubMed ID: 37712675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sudden cardiac death risk stratification and assessment: primary prevention based on ejection fraction criteria.
    Saba S
    Heart Fail Clin; 2011 Apr; 7(2):175-83, vii. PubMed ID: 21439496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mortality and Sudden Cardiac Death Risk Stratification Using the Noninvasive Combination of Wide QRS Duration and Late Gadolinium Enhancement in Idiopathic Dilated Cardiomyopathy.
    Marume K; Noguchi T; Tateishi E; Morita Y; Kamakura T; Ishibashi K; Noda T; Miura H; Nishimura K; Nakai M; Yamada N; Tsujita K; Anzai T; Kusano K; Ogawa H; Yasuda S
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e006233. PubMed ID: 29654132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.
    Epstein AE; Abraham WT; Bianco NR; Kern KB; Mirro M; Rao SV; Rhee EK; Solomon SD; Szymkiewicz SJ
    J Am Coll Cardiol; 2013 Nov; 62(21):2000-2007. PubMed ID: 23916930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved Beyond Guidelines for a Defibrillator in MADIT-CRT.
    Sherazi S; Shah F; Kutyifa V; McNitt S; Aktas MK; Polonsky B; Zareba W; Goldenberg I
    JACC Clin Electrophysiol; 2019 Oct; 5(10):1172-1181. PubMed ID: 31648742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of implantable cardioverter defibrillator on the prognosis of nonischemic dilated cardiomyopathy patients compared with standard medical treatments.
    Salehi Omran H; Naghashzadeh F; Irilouzadian R; Dolatshahi S; Hedayati Goudarzi MT; Salehi Omran MT
    Clin Cardiol; 2023 Jun; 46(6):674-679. PubMed ID: 37057368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT.
    Grimm W; Alter P; Maisch B
    Herz; 2004 May; 29(3):348-52. PubMed ID: 15167963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function.
    Schaer BA; Ammann P; Sticherling C; Zellweger MJ; Cron TA; Osswald S
    Int J Cardiol; 2006 Mar; 108(1):26-30. PubMed ID: 16516695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study.
    Grimm W; Christ M; Bach J; Müller HH; Maisch B
    Circulation; 2003 Dec; 108(23):2883-91. PubMed ID: 14623812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Left atrial booster pump function is an independent predictor of subsequent life-threatening ventricular arrhythmias in non-ischaemic cardiomyopathy.
    Negishi K; Negishi T; Zardkoohi O; Ching EA; Basu N; Wilkoff BL; Popović ZB; Marwick TH
    Eur Heart J Cardiovasc Imaging; 2016 Oct; 17(10):1153-60. PubMed ID: 26710819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.